These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12512389)

  • 1. Development of matrix metalloproteinase inhibitors in cancer therapy.
    Purcell WT; Rudek MA; Hidalgo M
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1189-227. PubMed ID: 12512389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metalloproteinases in tumor progression. Review].
    Arvelo F; Cotte C
    Invest Clin; 2006 Jun; 47(2):185-205. PubMed ID: 16886780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.
    Fingleton B
    Expert Opin Ther Targets; 2003 Jun; 7(3):385-97. PubMed ID: 12783574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis as a target for cancer therapy.
    Kaban K; Herbst RS
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1125-71. PubMed ID: 12512387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.
    Overall CM; Kleifeld O
    Nat Rev Cancer; 2006 Mar; 6(3):227-39. PubMed ID: 16498445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
    Coussens LM; Fingleton B; Matrisian LM
    Science; 2002 Mar; 295(5564):2387-92. PubMed ID: 11923519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of matrix metalloproteinases in patients with malignant tumors].
    Stanciūte D; Didziapetriene J; Kadziauskas J
    Medicina (Kaunas); 2004; 40(12):1143-50. PubMed ID: 15630339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy.
    Ryan ME; Golub LM
    Periodontol 2000; 2000 Oct; 24():226-38. PubMed ID: 11276869
    [No Abstract]   [Full Text] [Related]  

  • 10. Extracellular proteolysis and cancer: meeting summary and future directions.
    Matrisian LM; Sledge GW; Mohla S
    Cancer Res; 2003 Oct; 63(19):6105-9. PubMed ID: 14559785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of matrix metalloproteinase inhibitors in cancer therapy.
    Hidalgo M; Eckhardt SG
    J Natl Cancer Inst; 2001 Feb; 93(3):178-93. PubMed ID: 11158186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metalloproteinases: their role in arthritis and potential as therapeutic targets.
    Clark IM; Parker AE
    Expert Opin Ther Targets; 2003 Feb; 7(1):19-34. PubMed ID: 12556200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis.
    Curran S; Murray GI
    Eur J Cancer; 2000 Aug; 36(13 Spec No):1621-30. PubMed ID: 10959048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targets in the inhibition of angiogenesis.
    Dudek AZ; Pawlak WZ; Kirstein MN
    Expert Opin Ther Targets; 2003 Aug; 7(4):527-41. PubMed ID: 12885272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of extracellular matrix degradation enzyme for glioma invasion].
    Nakada M
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():55-60. PubMed ID: 16201500
    [No Abstract]   [Full Text] [Related]  

  • 17. Matrix metalloproteinase inhibitors.
    Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
    Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
    Rudek MA; Venitz J; Figg WD
    Pharmacotherapy; 2002 Jun; 22(6):705-20. PubMed ID: 12066962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential of proteasome inhibitors in cancer therapy.
    Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
    Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.
    Castro MM; Kandasamy AD; Youssef N; Schulz R
    Pharmacol Res; 2011 Dec; 64(6):551-60. PubMed ID: 21689755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.